How should a man with reduced ejaculate volume be evaluated and managed?

Evaluation and Management of Reduced Ejaculate Volume

A man with reduced ejaculate volume (<1.4 mL) requires systematic evaluation to identify the underlying cause—most commonly ejaculatory duct obstruction, congenital bilateral absence of vas deferens, or retrograde ejaculation—before any treatment can be initiated. 1

Initial Clinical Assessment

Critical Physical Examination Findings

• Palpate for vas deferens bilaterally to rule out congenital bilateral absence of vas deferens (CBAVD), which can be diagnosed by physical examination alone and accounts for a significant proportion of low-volume cases. 1, 2
• Assess testicular size and consistency: normal-sized testes (≥12 mL) suggest obstruction, while atrophic testes (<12 mL) indicate primary spermatogenic failure. 1, 2
• Examine for palpable varicoceles, as treatment of clinical (palpable) varicoceles improves semen parameters and fertility, whereas non-palpable varicoceles should not be treated. 1, 2
• Perform digital rectal examination to assess prostate size, consistency, and rule out prostatic pathology. 1, 2

Essential Laboratory Tests

• Check semen pH: acidic semen (pH <7.0) with low volume strongly suggests ejaculatory duct obstruction (EDO) or CBAVD. 1, 2
• Measure serum testosterone and FSH: low testosterone with low/normal FSH indicates hypogonadotropic hypogonadism, while elevated FSH (>7.6 IU/L) suggests primary testicular failure. 1, 2
• Perform post-ejaculatory urinalysis when volume is <1 mL (except in bilateral vasal agenesis or hypogonadism) to diagnose retrograde ejaculation. 1, 2
• Confirm with repeat semen analysis at least one month apart, with 2-3 days of abstinence before collection. 3

Imaging Studies—When and Why

Transrectal Ultrasound (TRUS) or Pelvic MRI

Reserve TRUS or pelvic MRI for suspected ejaculatory duct obstruction only—specifically when semen is acidic, volume <1.4 mL, with azoospermia or severe oligospermia with very low motility, normal testosterone, and palpable vas deferens. 1, 2

• Do not perform TRUS or pelvic MRI as part of initial evaluation in all men with low volume; this is a targeted study for high-suspicion cases. 1, 2
• Pelvic MRI can identify dilated seminal vesicles, ejaculatory ducts, and characterize prostate cysts (paramedian/ejaculatory duct cysts, midline Müllerian duct cysts) that cause obstruction. 1

Scrotal Ultrasound

• Avoid routine scrotal ultrasound for varicocele diagnosis—only palpable varicoceles warrant treatment, and imaging non-palpable varicoceles does not improve outcomes. 1, 2
• Scrotal ultrasound is indicated when physical examination is difficult, testicular mass is suspected, or testicular volume needs precise quantification. 3

Renal Ultrasound

• Mandatory for all patients with unilateral or bilateral vas deferens agenesis, as 26-75% of those with unilateral absence and 10% with bilateral absence have ipsilateral renal anomalies including renal agenesis. 3

Etiology-Based Treatment

Ejaculatory Duct Obstruction (EDO)

• Transurethral resection of ejaculatory ducts (TURED) is the definitive treatment for confirmed EDO on TRUS or MRI showing dilated seminal vesicles and ejaculatory ducts. 2
• Suspect EDO when ejaculate is acidic (pH <7.0), volume <1.4 mL, azoospermic or severely oligospermic with very low motility, normal testosterone, and palpable vas deferens. 1

Congenital Bilateral Absence of Vas Deferens (CBAVD)

• No medical or surgical treatment restores ejaculatory volume in CBAVD; proceed directly to sperm retrieval (testicular sperm extraction [TESE] or microsurgical epididymal sperm aspiration [MESA]) with intracytoplasmic sperm injection (ICSI) for fertility. 2, 3
• CFTR gene testing is mandatory for the female partner before proceeding with assisted reproduction, as pathogenic mutations can be transmitted to offspring. 3, 2
• Genetic counseling is required before conception due to the risk of transmitting CFTR mutations. 3

Clinical Varicocele

• Varicocelectomy improves semen parameters and may restore sperm in ejaculate for men with azoospermia, particularly those with hypospermatogenesis on histology. 2
• Treatment is indicated for palpable varicoceles with abnormal semen parameters. 2
• Subclinical (non-palpable) varicoceles should not be treated, as this does not improve semen parameters or fertility rates. 1, 2

Retrograde Ejaculation

• Diagnosed by post-ejaculatory urinalysis showing sperm in urine when ejaculate volume is <1 mL. 1, 2
• Treatment options include alpha-adrenergic agonists or sperm retrieval from post-ejaculatory urine for assisted reproduction. 4

Genetic Testing Before Treatment

Genetic testing is mandatory before proceeding with assisted reproductive technologies, as results impact counseling and treatment decisions. 2

• Karyotype testing is required for azoospermia or severe oligospermia (<5 million/mL). 1, 2
• Y-chromosome microdeletion analysis is mandatory for azoospermia or sperm concentration <1 million/mL. 1, 2
• Genetic counseling should precede ICSI, as genetic abnormalities may be transmitted to offspring. 2

Medication-Related Causes

5-Alpha Reductase Inhibitors

• Finasteride 5 mg daily reduces ejaculate volume by approximately 25%, while 1 mg daily has minimal effect (median decrease of 0.03 mL, not clinically significant). 1, 5
• If a patient is taking finasteride 5 mg for benign prostatic hyperplasia and desires fertility, consider switching to alpha-1 adrenoceptor antagonists, which do not significantly reduce ejaculate volume. 6

Antihypertensive Medications

• Hypertension and antihypertensive medication use are associated with lower ejaculate volume (2.8 mL vs. 2.9 mL in normotensive men) and reduced sperm motility. 7
• Counsel patients interested in future fertility regarding lifestyle modifications to treat hypertension before relying solely on medications. 7

Critical Pitfalls to Avoid

• Never start testosterone replacement therapy in men desiring fertility, as it suppresses endogenous spermatogenesis via negative feedback on FSH and LH, potentially causing prolonged azoospermia. 3, 2
• Do not delay genetic testing—results must be obtained before proceeding with assisted reproduction to properly counsel patients about transmission risks. 2
• Do not hunt for subclinical varicoceles with ultrasound—only palpable varicoceles benefit from treatment. 1, 2
• Do not perform TRUS or pelvic MRI routinely—reserve for cases with clear clinical suspicion of EDO (low volume, acidic, azoospermic semen with normal testosterone and palpable vas). 1, 2